Seed VC · Netherlands
Aglaia invests in oncology drug development companies with a proven ability to select and mature early-stage breakthrough inventions that have the potential to transform cancer treatment. The team has decades of experience in cancer research and brings hands-on involvement in designing R&D plans from early screening through clinical studies.
Business models
biotech_therapeutics
Customer segments
Researchers
Geography
Europe
+ 2 more deals. Score your deck to see the full investment history.
We never publish partner emails directly — score your deck to unlock contacts for the firms ranked as best-fit.
Aglaia writes first institutional checks where the founder + early product matter more than traction. The seed market is the most dispersed segment of venture; matching to thesis (sector, stage, geography) is where most cold outreach succeeds or fails. VCboom tracks Aglaia alongside 47,000+ other active investors, ranked weekly by recent-deal momentum, sector concentration, and partner activity.
Drop your pitch. AI scores it on the 8 dimensions VCs read for and ranks the 47,000+ active investors in the database by fit. Aglaia is one of them — and we'll tell you exactly where they sit in your top 100.